RecoveryRx® Postoperative Market

Postoperative pain is a common consequence of surgery and affects more than 80% of patients [1]. With more than 22 million surgeries (including both in-patient and ambulatory surgeries) performed every year in the U.S. [2], more than 15 million Americans are estimated to experience post-operative pain annually. Both the American Society of Anesthesiologists (ASA) and the American Pain Society (APS) recommend multi-modal analgesia, defined as the use of two or more analgesics which act by different mechanisms, for managing acute postoperative pain [3].

One non-pharmacologic modality that can be used to augment oral analgesics such as NSAIDs and opioids, is electroceutical therapy.  RecoveryRx^® is a commercially available medical device (BioElectronics Corporation, Frederick, MD, USA) that uses pulsed shortwave therapy (PSWT) to modulate afferent nerve activity. This wearable therapy is FDA cleared for the treatment of postoperative pain upon approval by a medical professional.

The evidence for clinical effectiveness of RecoveryRx, from two randomized, double-blinded and placebo-controlled studies investigating acute postoperative pain are listed below:

1. Cesarean section surgeries
2. Breast augmentation

These results were reviewed by the US FDA and resulted in the BioElectronics Corp. receiving a 510(k) clearance for RecoveryRx, indicated for the treatment of postoperative pain.

Click here to view RecoveryRx® Published Studies

References

[1]	Chou, Roger et.al., “Guidelines on the Management of Postoperative Pain,” American Pain Society, vol. 17, no. 2, pp. 131-157, 2016.
[2]	AHRQ, “Ambulatory In-patient surgeries,” February 2018. [Online]. Available: https://www.hcup-us.ahrq.gov/reports/statbriefs/sb223-Ambulatory-Inpatient-Surgeries-2014.pdf. [Accessed 7 January 2019].
[3]	ASA, “Practice Guidelines for Acute Pain Management in the Perioperative Setting,” Anesthisiology, vol. 116, no. 2, pp. 248-273, 2012.